Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q3 EPS of ($0.81), $0.07 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $16.9 million versus the consensus estimate of $12.62 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.